Molsid, pioneer in rapid antimicrobial resistance diagnostics, and Eurobio Scientific, a leading European in vitro diagnostics company, today announce a distribution agreement under which Eurobio Scientific will commercialize Molsid’s novel ResiScreen® Staph kit across key European territories.
The ResiScreen® Staph assay leverages Molsid’s patented SmartID® fluorogenic biotracer technology to deliver the only reliable phenotypic test currently on the market for detecting active BlaZ-encoded penicillinase in Staphylococcus aureus and coagulase-negative staphylococci. In a validation presented at ESCMID Global 2025 by Pr. Frédéric Laurent, Head of the French National Reference Center for Staphylococci, the SmartID® approach demonstrated 100 % sensitivity and 100 % specificity in detecting penicillinase activity in clinical staphylococcal isolates.
Under the terms of the agreement, Eurobio Scientific will assume commercial distribution of ResiScreen® Staph in major European countries, leveraging its extensive diagnostic network and relationships with hospital laboratories and reference centers. Molsid will remain responsible for manufacturing, regulatory compliance, and product support, in close coordination with Eurobio’s regional teams.
“We are delighted to partner with Eurobio Scientific,” said Stéphane Gavoille, General Manager at Molsid. “This agreement marks a major milestone in our mission to bring truly innovative phenotypic diagnostics into routine use. The strength of Eurobio’s European presence will enable microbiology labs to adopt ResiScreen® Staph more broadly, thereby improving antimicrobial stewardship.”
“Eurobio Scientific is pleased to expand our portfolio with this uniquely powerful phenotypic assay,” commented Jean-Michel CARLE, General Manager at Eurobio Scientific. “Antibiotic resistance diagnostics is a strategic growth area for us, and ResiScreen® Staph complements our existing offerings in molecular and immunoassay diagnostics. We believe this product will address a crucial unmet need in staphylococcal diagnostics across Europe.”
